Northern Trust
STRO icon

Northern Trust’s Sutro Biopharma STRO Stock Holding History

Northern Trust’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$826K Buy
33,166
+18,787
+131% +$340K ﹤0.01% 3425
2025
Q4 		$166K Buy
14,379
+2,167
+18% +$20.6K ﹤0.01% 4041
2025
Q3 		$106K Sell
12,212
-4,561
-27% -$38.8K ﹤0.01% 4120
2025
Q2 		$120K Sell
16,773
-46,619
-74% -$381K ﹤0.01% 4073
2025
Q1 		$412K Sell
63,392
-300
-0.5% -$4.72K ﹤0.01% 3651
2024
Q4 		$1.17M Buy
63,692
+1,449
+2% +$44.2K ﹤0.01% 3319
2024
Q3 		$2.15M Buy
62,243
+11,978
+24% +$470K ﹤0.01% 2957
2024
Q2 		$1.47M Buy
50,265
+1,627
+3% +$64.3K ﹤0.01% 3070
2024
Q1 		$2.75M Buy
48,638
+520
+1% +$23K ﹤0.01% 2797
2023
Q4 		$2.06M Sell
48,118
-464
-1% -$14.7K ﹤0.01% 2991
2023
Q3 		$1.69M Buy
48,582
+275
+0.6% +$12K ﹤0.01% 3031
2023
Q2 		$2.25M Buy
48,307
+2,816
+6% +$140K ﹤0.01% 2944
2023
Q1 		$2.1M Sell
45,491
-565
-1% -$35.9K ﹤0.01% 2918
2022
Q4 		$3.72M Buy
46,056
+5,379
+13% +$374K ﹤0.01% 2664
2022
Q3 		$2.26M Buy
40,677
+2,979
+8% +$176K ﹤0.01% 2955
2022
Q2 		$1.96M Sell
37,698
-1,404
-4% -$78.4K ﹤0.01% 3079
2022
Q1 		$3.21M Sell
39,102
-15,420
-28% -$1.47M ﹤0.01% 2846
2021
Q4 		$8.11M Buy
54,522
+920
+2% +$165K ﹤0.01% 2384
2021
Q3 		$10.1M Sell
53,602
-1,838
-3% -$349K ﹤0.01% 2258
2021
Q2 		$10.3M Buy
55,440
+21,008
+61% +$4.11M ﹤0.01% 2339
2021
Q1 		$7.84M Buy
34,432
+3,004
+10% +$713K ﹤0.01% 2461
2020
Q4 		$6.82M Buy
31,428
+9,347
+42% +$1.55M ﹤0.01% 2490
2020
Q3 		$2.22M Buy
22,081
+166
+0.8% +$15.7K ﹤0.01% 3015
2020
Q2 		$1.7M Buy
21,915
+9,147
+72% +$878K ﹤0.01% 3120
2020
Q1 		$1.3M Buy
12,768
+550
+5% +$57.8K ﹤0.01% 3083
2019
Q4 		$1.34M Buy
12,218
+76
+0.6% +$7.83K ﹤0.01% 3297
2019
Q3 		$1.1M Buy
12,142
+4,164
+52% +$420K ﹤0.01% 3363
2019
Q2 		$907K Buy
7,978
+491
+7% +$54.1K ﹤0.01% 3391
2019
Q1 		$852K Buy
7,487
+1,055
+16% +$110K ﹤0.01% 3411
2018
Q4 		$580K Buy
+6,432
New +$776K ﹤0.01% 3519

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Northern Trust's STRO Position: Q1 2026 in Review

Northern Trust increased its Sutro Biopharma (STRO) stake by 131% in Q1 2026, buying an estimated $340K and bringing the position to 33,166 shares worth $826K. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

Northern Trust first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $10.3M in Q2 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Northern Trust held 33,166 shares of Sutro Biopharma worth $826K as of Q1 2026.
  • Northern Trust bought 18,787 Sutro Biopharma shares in Q1 2026, an estimated $340K.
  • Sutro Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3425 holding.
  • Northern Trust first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • Northern Trust's Sutro Biopharma position peaked at $10.3M in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.